Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)

Oral Oncology

Volumn 45, Issue 11, 2009, Pages 986-990

  Locati, Laura D ^a   Perrone, Federica ^a   Losa, Marco ^a   Mela, Micol ^a   Casieri, Paola ^a   Orsenigo, Marta ^a   Cortelazzi, Barbara ^a   Negri, Tiziana ^a   Tamborini, Elena ^a   Quattrone, Pasquale ^a   Bossi, Paolo ^a   Rinaldi, Gaetana ^a   Bergamini, Cristiana ^a   Calderone, Rosa G ^a   Liberatoscioli, Cecilia ^a   Licitra, Lisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hormonal receptors; Immunohistochemistry; Salivary gland cancer; Tyrosine kinase receptors

Indexed keywords

ANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; PROGESTERONE RECEPTOR; STEM CELL FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ARTICLE; DEREGULATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SALIVARY GLAND CARCINOMA;

ADENOCARCINOMA; CARCINOMA; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, STEROID; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS;

EID: 70349925141     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.05.635     Document Type: Article

References (37)

1. Seifert G., and Sobin L.H. The World Health Organization's histological classification of salivary gland tumors. A commentary on the second edition. Cancer 70 (1992) 379-385
2. Barnes L, Eveson JW, Reichart P, et al. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005.
3. Batsakis J.G., Regezi J.A., Luna M.A., et al. Histogenesis of salivary gland neoplasms: a postulate with prognostic implications. J Laryngol Otol 103 (1989) 939-944
4. Tamborini E., Bonadiman L., Greco A., et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127 (2004) 294-299
5. Dagrada G.P., Mezzelani A., Alasio L., et al. HER-2/neu assessment in primary chemotherapy treated breast carcinoma: no evidence of gene profile changing. Breast Cancer Res Treat 80 (2003) 207-214
6. Martinez-Madrigal F., and Micheau C. Histology of the major salivary glands. Am J Surg Pathol 13 (1989) 879-899
7. Jeng Y.M., Lin C.Y., and Hsu H.C. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154 (2000) 107-111
8. Holst V.A., Marshall C.E., Moskaluk C.A., et al. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12 (1999) 956-960
9. Bernheim A., Toujani S., Saulnier P., et al. High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinoma. Lab Invest 88 (2008) 464-473
10. Hotte S.J., Winquist E.W., Lamont E., et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23 (2005) 585-590
11. Pfeffer M.R., Talmi Y., Catane R., et al. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43 (2007) 33-36
12. Negri T., Tamborini E., Dagrada G.P., Greco A., Staurengo S., Guzzo M., et al. TRK-A, HER-2/neu, and KIT expression/activation profiles in salivary gland carcinoma. Transl Oncol 1 (2008) 121-128
13. Glisson B., Colevas A.D., Haddad R., et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 10 (2004) 944-946
14. Kleinsasser O., Klein H.J., and Hubner G. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 192 (1968) 100-105
15. Birek C., Lui E., Jordan R.C., et al. Analysis of c-erbB-2 amplification in salivary gland tumours by differential polymerase chain reaction. Eur J Cancer B Oral Oncol 30B (1994) 47-50
16. Dagrada G.P., Negri T., Tamborini E., et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 44 (2004) 301-302
17. Skalova A., Starek I., Vanecek T., et al. Amplification and overexpression of HER-2/neu in parotid gland salivary duct carcinoma. Immunohistochemical study and fluorescence in situ hybridization. Cesk Patol 38 1 (2002) 27-34
18. Press M.F., Pike M.C., Hung G., et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54 (1994) 5675-5682
19. Sugano S., Mukai K., Tsuda H., et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 102 (1992) 923-927
20. Nagler R.M., Kerner H., Ben Eliezer S., et al. Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies. Oncology 64 (2003) 389-398
21. Haddad R., Colevas A.D., Krane J.F., et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39 (2003) 724-727
22. Locati L.D., Rinaldi G., Bossi P., et al. Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol 41 (2005) 97-98
23. Kapadia S.B., and Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol 11 (1998) 1033-1038
24. Fan C.Y., Wang J., and Barnes E.L. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 24 (2000) 579-586
25. Fan C.Y., Melhem M.F., Hosal A.S., et al. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 127 (2001) 1075-1079
26. Moriki T., Ueta S., Takahashi T., et al. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 93 (2001) 344-350
27. Hoang M.P., Callender D.L., Sola Gallego J.J., et al. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Int J Oncol 19 (2001) 865-871
28. Barnes L., Rao U., Contis L., et al. Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol 78 (1994) 74-80
29. Lewis J.E., McKinney B.C., Weiland L.H., et al. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 77 (1996) 223-230
30. van der Hulst R.W., van Krieken J.H., van der Kwast T.H., et al. Partial remission of parotid gland carcinoma after goserelin. Lancet 344 (1994) 817
31. Locati L.D., Quattrone P., Bossi P., et al. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 14 (2003) 1327-1328
32. Gibbons M.D., Manne U., Carroll W.R., et al. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 111 (2001) 1373-1378
33. Katopodi E., Patsouris E., Papanikolaou V., et al. Immunohistochemical detection of epidermal growth factor and its receptor in salivary gland carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 (2003) 266-268
34. Vered M., Braunstein E., and Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24 (2002) 632-636
35. Glisson B.S., Blumenschein G., Francisco M., et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. ASCO An Meet Proc 23 (2005) 508s
36. Agulnik M., Cohen E.W., Cohen R.B., et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25 (2007) 3978-3984
37. Locati L.D., Bossi P., Perrone F., et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45 (2008) 574-578